Bristol-Myers Squibb’s shares have fallen sharply in pre-opening trading after mixed results from its cancer immunotherapy Opdivo in lung cancer. BMS is playing catch-up with Merck & Co’s immunotherapy Keytruda (pembrolizumab), which is now es...
Original Article: BMS shares fall on mixed cancer immunotherapy results